Development of an amplicon-based sequencing approach in response to the global emergence of mpox.
Journal
PLoS biology
ISSN: 1545-7885
Titre abrégé: PLoS Biol
Pays: United States
ID NLM: 101183755
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
12
01
2023
accepted:
05
05
2023
medline:
15
6
2023
pubmed:
13
6
2023
entrez:
13
6
2023
Statut:
epublish
Résumé
The 2022 multicountry mpox outbreak concurrent with the ongoing Coronavirus Disease 2019 (COVID-19) pandemic further highlighted the need for genomic surveillance and rapid pathogen whole-genome sequencing. While metagenomic sequencing approaches have been used to sequence many of the early mpox infections, these methods are resource intensive and require samples with high viral DNA concentrations. Given the atypical clinical presentation of cases associated with the outbreak and uncertainty regarding viral load across both the course of infection and anatomical body sites, there was an urgent need for a more sensitive and broadly applicable sequencing approach. Highly multiplexed amplicon-based sequencing (PrimalSeq) was initially developed for sequencing of Zika virus, and later adapted as the main sequencing approach for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Here, we used PrimalScheme to develop a primer scheme for human monkeypox virus that can be used with many sequencing and bioinformatics pipelines implemented in public health laboratories during the COVID-19 pandemic. We sequenced clinical specimens that tested presumptively positive for human monkeypox virus with amplicon-based and metagenomic sequencing approaches. We found notably higher genome coverage across the virus genome, with minimal amplicon drop-outs, in using the amplicon-based sequencing approach, particularly in higher PCR cycle threshold (Ct) (lower DNA titer) samples. Further testing demonstrated that Ct value correlated with the number of sequencing reads and influenced the percent genome coverage. To maximize genome coverage when resources are limited, we recommend selecting samples with a PCR Ct below 31 Ct and generating 1 million sequencing reads per sample. To support national and international public health genomic surveillance efforts, we sent out primer pool aliquots to 10 laboratories across the United States, United Kingdom, Brazil, and Portugal. These public health laboratories successfully implemented the human monkeypox virus primer scheme in various amplicon sequencing workflows and with different sample types across a range of Ct values. Thus, we show that amplicon-based sequencing can provide a rapidly deployable, cost-effective, and flexible approach to pathogen whole-genome sequencing in response to newly emerging pathogens. Importantly, through the implementation of our primer scheme into existing SARS-CoV-2 workflows and across a range of sample types and sequencing platforms, we further demonstrate the potential of this approach for rapid outbreak response.
Identifiants
pubmed: 37310918
doi: 10.1371/journal.pbio.3002151
pii: PBIOLOGY-D-23-00106
pmc: PMC10263305
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3002151Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright: © 2023 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: NDG is a consultant for Tempus Labs and the National Basketball Association for work related to COVID-19. All other authors have declared that no competing interests exist.
Références
Bioinformatics. 2009 Jun 1;25(11):1422-3
pubmed: 19304878
J Clin Virol. 2006 Jul;36(3):194-203
pubmed: 16731033
Nature. 2020 Sep;585(7825):357-362
pubmed: 32939066
J Virol Methods. 2010 Oct;169(1):223-7
pubmed: 20643162
J Virol. 2005 Oct;79(20):13139-49
pubmed: 16189015
Science. 2022 Nov 4;378(6619):560-565
pubmed: 36264825
Nat Microbiol. 2019 Jan;4(1):10-19
pubmed: 30546099
J Clin Microbiol. 2022 Dec 21;60(12):e0165522
pubmed: 36445125
Lancet Infect Dis. 2022 Aug;22(8):1153-1162
pubmed: 35623380
Science. 2022 Oct 7;378(6615):eabq5358
pubmed: 36108049
Euro Surveill. 2022 Jul;27(28):
pubmed: 35837964
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Bioengineering (Basel). 2021 May 07;8(5):
pubmed: 34066939
Cell Host Microbe. 2023 Jun 14;31(6):861-873
pubmed: 36921604
Nat Genet. 2022 Apr;54(4):499-507
pubmed: 35347305
N Engl J Med. 2022 Aug 25;387(8):679-691
pubmed: 35866746
J Clin Microbiol. 2004 Mar;42(3):1207-13
pubmed: 15004077
Science. 2014 Sep 12;345(6202):1369-72
pubmed: 25214632
PLoS Biol. 2022 Aug 23;20(8):e3001769
pubmed: 35998195
Emerg Infect Dis. 2022 Dec;28(12):2520-2523
pubmed: 36178142
Nat Protoc. 2017 Jun;12(6):1261-1276
pubmed: 28538739
Genome Biol. 2015 Jul 30;16(1):155
pubmed: 27391693
Lancet Microbe. 2022 Aug;3(8):e554-e555
pubmed: 35688169
bioRxiv. 2020 Sep 04;:
pubmed: 32908977
Nat Biotechnol. 2017 Sep 12;35(9):833-844
pubmed: 28898207
Nat Med. 2022 Aug;28(8):1569-1572
pubmed: 35750157
Nat Rev Genet. 2019 Jun;20(6):341-355
pubmed: 30918369
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750
Appl Environ Microbiol. 2008 Jan;74(1):32-7
pubmed: 17965204
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
N Engl J Med. 2023 Mar 30;388(13):1246-1247
pubmed: 36884032
J Virol Methods. 2011 Aug;175(2):163-9
pubmed: 21635922
J Virol. 2018 Jun 29;92(14):
pubmed: 29720522
MMWR Morb Mortal Wkly Rep. 2022 Jul 15;71(28):904-907
pubmed: 35834423